These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

836 related articles for article (PubMed ID: 21890902)

  • 1. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA.
    Karikó K; Muramatsu H; Ludwig J; Weissman D
    Nucleic Acids Res; 2011 Nov; 39(21):e142. PubMed ID: 21890902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.
    Karikó K; Muramatsu H; Welsh FA; Ludwig J; Kato H; Akira S; Weissman D
    Mol Ther; 2008 Nov; 16(11):1833-40. PubMed ID: 18797453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice.
    Andries O; Mc Cafferty S; De Smedt SC; Weiss R; Sanders NN; Kitada T
    J Control Release; 2015 Nov; 217():337-44. PubMed ID: 26342664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin.
    Karikó K; Muramatsu H; Keller JM; Weissman D
    Mol Ther; 2012 May; 20(5):948-53. PubMed ID: 22334017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo.
    Kauffman KJ; Mir FF; Jhunjhunwala S; Kaczmarek JC; Hurtado JE; Yang JH; Webber MJ; Kowalski PS; Heartlein MW; DeRosa F; Anderson DG
    Biomaterials; 2016 Dec; 109():78-87. PubMed ID: 27680591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L.
    Anderson BR; Muramatsu H; Jha BK; Silverman RH; Weissman D; Karikó K
    Nucleic Acids Res; 2011 Nov; 39(21):9329-38. PubMed ID: 21813458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes.
    Pardi N; Tuyishime S; Muramatsu H; Kariko K; Mui BL; Tam YK; Madden TD; Hope MJ; Weissman D
    J Control Release; 2015 Nov; 217():345-51. PubMed ID: 26264835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleoside Modified mRNA Vaccines for Infectious Diseases.
    Pardi N; Weissman D
    Methods Mol Biol; 2017; 1499():109-121. PubMed ID: 27987145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA.
    Verbeke R; Lentacker I; Wayteck L; Breckpot K; Van Bockstal M; Descamps B; Vanhove C; De Smedt SC; Dewitte H
    J Control Release; 2017 Nov; 266():287-300. PubMed ID: 28987878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPLC purification of in vitro transcribed long RNA.
    Weissman D; Pardi N; Muramatsu H; Karikó K
    Methods Mol Biol; 2013; 969():43-54. PubMed ID: 23296926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation.
    Anderson BR; Muramatsu H; Nallagatla SR; Bevilacqua PC; Sansing LH; Weissman D; Karikó K
    Nucleic Acids Res; 2010 Sep; 38(17):5884-92. PubMed ID: 20457754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining optimized properties of modified mRNA to enhance virus- and DNA- independent protein expression in adult stem cells and fibroblasts.
    Hausburg F; Na S; Voronina N; Skorska A; Müller P; Steinhoff G; David R
    Cell Physiol Biochem; 2015; 35(4):1360-71. PubMed ID: 25720503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density.
    Svitkin YV; Cheng YM; Chakraborty T; Presnyak V; John M; Sonenberg N
    Nucleic Acids Res; 2017 Jun; 45(10):6023-6036. PubMed ID: 28334758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transfection of Human Keratinocytes with Nucleoside-Modified mRNA Encoding CPD-Photolyase to Repair DNA Damage.
    Boros G; Karikó K; Muramatsu H; Miko E; Emri E; Hegedűs C; Emri G; Remenyik É
    Methods Mol Biol; 2016; 1428():219-28. PubMed ID: 27236802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Epitranscriptome in Translation Regulation.
    Peer E; Moshitch-Moshkovitz S; Rechavi G; Dominissini D
    Cold Spring Harb Perspect Biol; 2019 Aug; 11(8):. PubMed ID: 30037968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification.
    Vaidyanathan S; Azizian KT; Haque AKMA; Henderson JM; Hendel A; Shore S; Antony JS; Hogrefe RI; Kormann MSD; Porteus MH; McCaffrey AP
    Mol Ther Nucleic Acids; 2018 Sep; 12():530-542. PubMed ID: 30195789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concerted 2-5A-Mediated mRNA Decay and Transcription Reprogram Protein Synthesis in the dsRNA Response.
    Rath S; Prangley E; Donovan J; Demarest K; Wingreen NS; Meir Y; Korennykh A
    Mol Cell; 2019 Sep; 75(6):1218-1228.e6. PubMed ID: 31494033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mRNA transcript therapy.
    Weissman D
    Expert Rev Vaccines; 2015 Feb; 14(2):265-81. PubMed ID: 25359562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic Cell Targeting mRNA Lipopolyplexes Combine Strong Antitumor T-Cell Immunity with Improved Inflammatory Safety.
    Van der Jeught K; De Koker S; Bialkowski L; Heirman C; Tjok Joe P; Perche F; Maenhout S; Bevers S; Broos K; Deswarte K; Malard V; Hammad H; Baril P; Benvegnu T; Jaffrès PA; Kooijmans SAA; Schiffelers R; Lienenklaus S; Midoux P; Pichon C; Breckpot K; Thielemans K
    ACS Nano; 2018 Oct; 12(10):9815-9829. PubMed ID: 30256609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response.
    Foster JB; Choudhari N; Perazzelli J; Storm J; Hofmann TJ; Jain P; Storm PB; Pardi N; Weissman D; Waanders AJ; Grupp SA; Karikó K; Resnick AC; Barrett DM
    Hum Gene Ther; 2019 Feb; 30(2):168-178. PubMed ID: 30024272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.